ROIV RSI Chart
Last 7 days
-3.6%
Last 30 days
2.2%
Last 90 days
3.5%
Trailing 12 Months
22.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 61.3M | 81.9M | 102.6M | 123.2M |
2022 | 55.3M | 328.0M | 600.7M | 873.4M |
2021 | 23.8M | 30.0M | 42.6M | 61.2M |
2020 | 67.7M | 56.7M | 45.7M | 34.8M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 28, 2024 | pulik richard | sold (taxes) | -25,810 | 11.03 | -2,340 | cfo |
Apr 24, 2024 | momtazee james c | sold (taxes) | -3,193 | 10.9 | -293 | - |
Apr 24, 2024 | fitzgerald meghan | acquired | - | - | 1,261 | - |
Apr 24, 2024 | fitzgerald meghan | sold (taxes) | -904 | 10.9 | -83.00 | - |
Apr 24, 2024 | momtazee james c | acquired | - | - | 1,490 | - |
Apr 24, 2024 | oren ilan | acquired | - | - | 2,121 | - |
Apr 24, 2024 | epperly melissa b, | acquired | - | - | 1,146 | - |
Apr 24, 2024 | oren ilan | sold (taxes) | -588 | 10.9 | -54.00 | - |
Apr 24, 2024 | epperly melissa b, | sold (taxes) | -1,340 | 10.9 | -123 | - |
Apr 22, 2024 | pulik richard | acquired | - | - | 38,685 | cfo |
Which funds bought or sold ROIV recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | OSAIC HOLDINGS, INC. | added | 6,631 | 22,344 | 22,703 | -% |
May 10, 2024 | ACADIAN ASSET MANAGEMENT LLC | new | - | 72,000 | 72,000 | -% |
May 10, 2024 | BlackRock Inc. | added | 73.93 | 147,770,000 | 381,416,000 | 0.01% |
May 10, 2024 | CIBC Private Wealth Group, LLC | new | - | 1,043 | 1,043 | -% |
May 10, 2024 | TIFF ADVISORY SERVICES, LLC | new | - | 12,097,300 | 12,097,300 | 5.28% |
May 10, 2024 | LPL Financial LLC | added | 92.8 | 181,724 | 406,212 | -% |
May 10, 2024 | Edgestream Partners, L.P. | sold off | -100 | -402,202 | - | -% |
May 10, 2024 | Rubric Capital Management LP | added | 5.26 | -2,570,000 | 210,800,000 | 6.23% |
May 10, 2024 | JPMORGAN CHASE & CO | added | 118 | 4,992,870 | 9,736,870 | -% |
May 10, 2024 | CITIGROUP INC | added | 130 | 4,817,350 | 8,948,940 | 0.01% |
Unveiling Roivant Sciences Ltd.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Roivant Sciences Ltd.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
Roivant Sciences Ltd. News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Revenue | 0.1% | 37,140,000 | 37,101,000 | 21,624,000 | 27,376,000 | 22,837,750 | 18,299,500 | 13,761,250 | 9,223,000 | 24,341,000 | 13,987,000 | 7,735,000 | 15,146,000 | 5,750,000 | 1,323,000 | - | - |
Operating Expenses | 3.5% | 324,667,000 | 313,555,000 | 298,037,000 | 261,542,000 | 395,129,000 | 293,299,000 | 286,628,000 | 276,026,000 | 270,364,000 | 698,416,000 | 162,122,000 | 555,980,000 | 264,820,000 | 157,864,000 | 116,029,000 | - |
S&GA Expenses | 20.0% | 197,282,000 | 164,355,000 | 156,190,000 | 125,510,000 | 168,261,000 | 157,663,000 | 149,072,000 | 138,973,000 | 115,530,000 | 437,776,000 | 82,754,000 | 3,934,458 | 61,875,000 | 59,740,000 | 57,115,000 | - |
R&D Expenses | -6.3% | 123,717,000 | 131,984,000 | 125,133,000 | 131,857,000 | 125,533,000 | 131,995,000 | 135,830,000 | 135,077,000 | 137,345,000 | 132,098,000 | 78,515,000 | -121,778,000 | 202,261,000 | 97,409,000 | 58,734,000 | - |
EBITDA Margin | 411.1% | 35.09 | -11.28 | -14.65 | -19.22 | -1.52 | -2.08 | -3.54 | -16.47 | - | - | - | - | - | - | - | - |
Interest Expenses | 2.1% | 9,444,000 | 9,247,000 | 8,912,000 | 8,575,000 | 8,446,000 | 8,335,000 | 2,612,000 | - | - | - | - | - | - | - | - | - |
Income Taxes | 583.3% | 25,672,000 | 3,757,000 | 1,752,000 | -3,793,000 | 2,819,000 | 2,165,000 | 3,999,000 | -163,000 | 38,000 | 401,000 | 93,000 | 19,504 | -224,000 | 711,000 | 1,221,000 | - |
Earnings Before Taxes | 1657.4% | 5,098,337,000 | -327,361,000 | -326,093,000 | -179,216,000 | -382,077,000 | -313,756,000 | -349,785,000 | -291,476,000 | -306,047,000 | -225,239,000 | -100,985,000 | 19,038,604 | -275,821,000 | -52,787,000 | -6,756,000 | - |
EBT Margin | 392.3% | 34.61 | -11.84 | -15.28 | -19.99 | -1.53 | -2.10 | -3.57 | -16.71 | -10.02 | -13.68 | -13.71 | -13.29 | -16.13 | -12.26 | -9.89 | -8.29 |
Net Income | 1639.1% | 5,096,184,000 | -331,118,000 | -327,845,000 | -10,464,000 | -352,014,000 | -315,921,000 | -353,784,000 | -252,035,000 | -284,536,000 | -225,640,000 | -101,078,000 | 19,019,100 | -261,029,000 | -53,498,000 | -7,977,000 | - |
Net Income Margin | 460.8% | 35.92 | -9.96 | -12.65 | -16.65 | -1.43 | -1.97 | -3.40 | -15.61 | -9.68 | -13.34 | -13.24 | -12.75 | 34.53 | 26.25 | 21.17 | 17.74 |
Free Cashflow | -7.2% | -210,807,000 | -196,702,000 | -250,335,000 | -180,710,000 | -223,101,000 | -192,731,000 | -259,541,000 | -153,732,000 | -274,567,000 | -123,357,000 | -143,509,000 | -4,327,983 | -236,966,000 | -99,348,000 | -111,473,000 | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q1 |
Assets | 254.0% | 7,313 | 2,066 | 2,137 | 2,390 | 2,203 | 2,216 | 2,600 | 2,585 | 2,799 | 3,103 | 2,455 | 2,590 | 413 | 2,477 |
Current Assets | 338.7% | 6,807 | 1,552 | 1,561 | 1,799 | 1,646 | 1,715 | 2,039 | 2,147 | 2,288 | 2,556 | 2,058 | 2,187 | 2.00 | 2,219 |
Cash Equivalents | 373.7% | 6,671 | 1,408 | 1,434 | 1,677 | 1,541 | 1,613 | 1,956 | 2,074 | 2,226 | 2,509 | 2,008 | 2,142 | 2,153 | 2,269 |
Net PPE | -10.7% | 22.00 | 24.00 | 36.00 | 39.00 | 37.00 | 39.00 | 32.00 | 26.00 | 22.00 | 17.00 | 16.00 | 15.00 | - | 9.00 |
Liabilities | -1.6% | 728 | 740 | 803 | 782 | 776 | 701 | 823 | 524 | 530 | 652 | 475 | 528 | 64.00 | 368 |
Current Liabilities | -7.8% | 245 | 266 | 245 | 272 | 244 | 231 | 329 | 184 | 161 | 303 | 209 | 219 | 1.00 | 92.00 |
Short Term Borrowings | - | - | - | - | - | - | - | 33.00 | - | - | - | - | - | - | - |
Long Term Debt | 3.6% | 403 | 389 | 385 | 376 | 375 | 376 | 384 | 210 | 172 | 168 | 155 | 150 | - | 89.00 |
LT Debt, Current | -6.7% | 46.00 | 49.00 | 44.00 | 41.00 | 38.00 | 36.00 | - | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | 210 | 204 | 200 | 186 | 170 | - | 109 |
Shareholder's Equity | 359.4% | 6,090 | 1,326 | 1,334 | 1,158 | 1,427 | 1,514 | 1,755 | 2,039 | 2,247 | 2,428 | 1,957 | 2,040 | 2,171 | 2,086 |
Retained Earnings | 116.6% | 727 | -4,368 | -4,100 | -3,772 | -3,700 | -3,387 | -3,095 | -2,763 | -2,493 | -2,200 | -2,000 | -1,918 | -10.77 | -1,109 |
Additional Paid-In Capital | 1.3% | 5,390 | 5,321 | 4,982 | 4,933 | 4,695 | 4,539 | 4,475 | 4,422 | 4,360 | 4,246 | 3,825 | 3,815 | 16.00 | 3,144 |
Shares Outstanding | 0.5% | 805 | 801 | 767 | 760 | 713 | 698 | 696 | 695 | 687 | 650 | 650 | 652 | 630 | 629 |
Minority Interest | 31.2% | 495 | 377 | 423 | 450 | 472 | 354 | 371 | 382 | 382 | 390 | 234 | 242 | - | 54.00 |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 |
Cashflow From Operations | -7.1% | -210,452 | -196,427 | -249,932 | -179,088 | -222,593 | -189,630 | -252,082 | -147,469 | -268,494 | -120,596 | -141,170 | -237 | -236,859 | -98,045 | -111,167 | - |
Share Based Compensation | 10.2% | 54,325 | 49,318 | 49,260 | 25,277 | 57,731 | 61,979 | 72,794 | 77,159 | 71,216 | 397,312 | 19,269 | 39,442 | 17,324 | 13,914 | 14,278 | - |
Cashflow From Investing | 14456.4% | 5,233,041 | -36,451 | 105 | 113,553 | -3,511 | -146,852 | -7,459 | -5,702 | -6,073 | 317,409 | -2,339 | 200,284 | -107 | -1,864 | -25,641 | - |
Cashflow From Financing | 13.8% | 236,639 | 207,872 | 7,477 | 210,332 | 154,495 | -7,341 | 141,976 | 1,070 | -8,422 | 303,934 | 10,210 | 5.00 | 464 | 175,956 | 181,130 | - |
Buy Backs | - | - | - | - | - | - | -8,329 | 8,329 | - | - | 2,247 | - | - | - | - | 113 | - |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues: | ||||
Revenue, net | $ 37,140 | $ 17,052 | $ 95,865 | $ 33,904 |
Operating expenses: | ||||
Cost of revenues | 3,668 | 3,586 | 11,148 | 8,953 |
Research and development (includes $7,475 and $6,888 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $24,305 and $26,548 for the nine months ended December 31, 2023 and 2022, respectively) | 123,717 | 125,533 | 380,834 | 393,358 |
Acquired in-process research and development | 0 | 97,749 | 26,450 | 97,749 |
Selling, general and administrative (includes $46,944 and $50,741 of share-based compensation expense for the three months ended December 31, 2023 and 2022 and $128,445 and $165,771 for the nine months ended December 31, 2023 and 2022, respectively) | 197,282 | 168,261 | 517,827 | 474,996 |
Total operating expenses | 324,667 | 395,129 | 936,259 | 975,056 |
Gain on sale of Telavant net assets | 5,348,410 | 0 | 5,348,410 | 0 |
Income (loss) from operations | 5,060,883 | (378,077) | 4,508,016 | (941,152) |
Change in fair value of investments | 10,467 | (25,948) | 63,880 | 53,277 |
Change in fair value of debt and liability instruments | 9,331 | 62,360 | 85,376 | 90,032 |
Gain on deconsolidation of subsidiaries | 0 | (12,514) | (17,354) | (29,276) |
Interest income | (31,953) | (10,249) | (62,967) | (17,900) |
Interest expense | 9,444 | 8,446 | 27,603 | 19,393 |
Other income, net | (34,743) | (18,095) | (33,405) | (11,060) |
Net income (loss) before income taxes | 5,098,337 | (382,077) | 4,444,883 | (1,045,618) |
Income tax expense | 25,672 | 2,819 | 31,181 | 8,983 |
Net income (loss) | 5,072,665 | (384,896) | 4,413,702 | (1,054,601) |
Net loss attributable to noncontrolling interests | (23,519) | (32,882) | (86,339) | (79,188) |
Net income (loss) attributable to Roivant Sciences Ltd. | $ 5,096,184 | $ (352,014) | $ 4,500,041 | $ (975,413) |
Net income (loss) per common share: | ||||
Net income (loss) per common share - basic (in dollars per share) | $ 6.37 | $ (0.49) | $ 5.79 | $ (1.39) |
Net income (loss) per common share - diluted (in dollars per share) | $ 6.03 | $ (0.49) | $ 5.46 | $ (1.39) |
Weighted average shares outstanding: | ||||
Weighted average shares outstanding, basic (in shares) | 800,587,716 | 713,319,399 | 776,759,728 | 703,054,773 |
Weighted average shares outstanding, diluted (in shares) | 844,461,685 | 713,319,399 | 824,310,013 | 703,054,773 |
Product Revenue, Net [Member] | ||||
Revenues: | ||||
Revenue, net | $ 20,666 | $ 9,244 | $ 55,749 | $ 14,354 |
License, Milestone and Other Revenue [Member] | ||||
Revenues: | ||||
Revenue, net | $ 16,474 | $ 7,808 | $ 40,116 | $ 19,550 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Mar. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 6,670,810 | $ 1,676,813 |
Other current assets | 135,923 | 121,774 |
Total current assets | 6,806,733 | 1,798,587 |
Property and equipment, net | 21,857 | 39,086 |
Operating lease right-of-use assets | 46,898 | 53,251 |
Investments measured at fair value | 239,927 | 304,317 |
Intangible assets, net | 150,415 | 144,881 |
Other assets | 46,849 | 49,482 |
Total assets | 7,312,679 | 2,389,604 |
Current liabilities: | ||
Accounts payable | 35,226 | 37,830 |
Accrued expenses | 122,148 | 167,129 |
Operating lease liabilities | 10,477 | 11,693 |
Current portion of long-term debt (includes $26,950 and $26,940 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively) | 45,706 | 40,720 |
Other current liabilities | 31,342 | 15,076 |
Total current liabilities | 244,899 | 272,448 |
Liability instruments measured at fair value | 28,374 | 63,546 |
Operating lease liabilities, noncurrent | 47,059 | 53,476 |
Long-term debt, net of current portion (includes $194,560 and $180,700 accounted for under the fair value option at December 31, 2023 and March 31, 2023, respectively) | 403,337 | 375,515 |
Other liabilities | 4,428 | 17,032 |
Total liabilities | 728,097 | 782,017 |
Commitments and contingencies (Note 11) | ||
Shareholders' equity: | ||
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 804,890,910 and 760,143,393 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively | 0 | 0 |
Additional paid-in capital | 5,390,260 | 4,933,137 |
Retained earnings / (accumulated deficit) | 727,287 | (3,772,754) |
Accumulated other comprehensive loss | (27,784) | (2,617) |
Shareholders' equity attributable to Roivant Sciences Ltd. | 6,089,763 | 1,157,766 |
Noncontrolling interests | 494,819 | 449,821 |
Total shareholders' equity | 6,584,582 | 1,607,587 |
Total liabilities and shareholders' equity | $ 7,312,679 | $ 2,389,604 |